Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

NCT04548752 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

88

Enrollment

NIH

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
DRUG: Olaparib
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)